CBS and colonic neoplasm: In summary, the current findings provide additional proof-of-concept that CBS is a significant antitumor target in colon cancer and support continued efforts to investigate and eventually clinically develop novel antitumor therapeutics based on CBS inhibition; perhaps in conjunction with the validation of a suitable biomarker (e.g., lanthionine) to identify a high CBS-expressor (and likely a best-responder) colon cancer target population.